Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab SC in RA (Ac-Cute)
NCT01951170Phase 3Completed
- Sponsor
- Roche
- Start
- Nov 2013
- Primary completion
- Aug 2015
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tocilizumab in rheumatoid arthritis (RA), sponsored by Roche. Primary endpoint: Change From Baseline in Genant-modified Total Sharp Score at 24 weeks. Started Nov 2013; status: completed.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01951170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01951170.